University discoveries and intellectual property rights: from Bothrops jararaca bradykinin potentiating peptides to angiotensin converting enzyme inhibitors
Ferreira, S.H.
Brazilian Journal of Medical and Biological Research 27(8): 1693-1698
1994
ISSN/ISBN: 0100-879X PMID: 7749362 Document Number: 436804
The academic basic research which led to the discovery of bradykinin potentiating peptides, the drug prototype for the new class of angiotensin converting enzyme inhibitors for the treatment of hypertension, is described. This case study is used to illustrate the situation of the academic scientist and his intellectual property rights for discoveries made at the University.
Document emailed within 1 workday
Related Documents
Brown, N.J.; Ryder, D.; Gainer, J.V.; Morrow, J.D.; Nadeau, J. 1996: Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin Journal of Pharmacology and Experimental Therapeutics 279(2): 703-712Galinier, M.; Pathak, A.; Baixas, C.; Alhabaj, S.; Fallouh, V.; Roncali, J.; Schmutz, L.; Massabuau, P.; Fauvel, J.M.; Bounhoure, J.P. 2002: Effects of bradykinin in the cardiovascular effects of angiotensin-converting enzyme inhibitors Archives des Maladies du Coeur et des Vaisseaux 95 Spec 4(5 Spec 4: 37-40
Campbell, D.J.; Anastasopoulos, F.; Duncan, A.M.; James, G.M.; Kladis, A.; Briscoe, T.A. 1998: Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats Journal of Pharmacology and Experimental Therapeutics 287(2): 567-577
Ganten, D.; Mullins, J.; Lindpaintner, K. 1989: The tissue renin-angiotensin system: a target for angiotensin-converting enzyme inhibitors Journal of Human Hypertension 3(Suppl 1): 63-70
De Paz, S.; Martín, A.B.; Iglesias, A.; Domínguez, A.R. 1999: Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin Ii receptor antagonists Medicina Clinica 113(19): 759
Jover, B.; Mimran, A. 1994: Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 12(9): S3-S9
Krzesinski, J.M.; Montrieux, C.; Scheen, A.J. 2006: Angiotensin converting enzyme inhibitors or angiotensin Ii receptor blocker in cardiovascular and renal pathology in 2006: what does EBM teach us? Revue Medicale de Liege 61(5-6): 414-422
Surabenjawong, U.; Thunpiphat, N.; Chatsiricharoenkul, S.; Monsomboon, A. 2013: Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers Journal of the Medical Association of Thailand 96(8): 905-910
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin converting enzyme inhibitors and angiotensin Ii receptor blockers on angiogenesis of gastric cancer in a nude mouse model Zhonghua Wei Chang Wai Ke Za Zhi 11(6): 565-568
Johnston, C.I.; Iansek, R.; Millar, J.A.; McGrath, B.P.; Matthews, P.G. 1981: Vasoactive peptides and hypertension: role of angiotensin converting enzyme Australian and New Zealand Journal of Medicine 11(Suppl 1): 59-63
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin-converting enzyme inhibitors and angiotensin Ii type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model Chinese Medical Journal 121(21): 2167-2171
Jasik, M.; Zdrojewicz, Z.; Stawicki, S. 1999: The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands Wiadomosci Lekarskie 52(3-4): 202-210
Squire, I.B.; MacFayden, R.J.; Reid, J.L.; Devlin, A.; Lees, K.R. 1996: Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure Journal of Cardiovascular Pharmacology 27(5): 657-666
Inzhutova, A.I.; Salmina, A.B.; Petrova, M.M. 2007: Pronounced homeostatic action of angiotensin converting enzyme inhibitors with high affinity to tissue renin-angiotensin-aldosterone system on cellular membranes Kardiologiia 47(8): 49-52
Humke, U.; Levens, N.; Wood, J.; Hofbauer, K. 1992: The acute renal actions of angiotensin converting enzyme inhibitors in the sodium-depleted conscious primate are mediated by inhibition of the renin-angiotensin system Journal of Pharmacology and Experimental Therapeutics 260(1): 29-35
Rizzoni, D. 1991: Angiotensin-converting enzyme inhibitors Recenti Progressi in Medicina 82(4): 251-252
Dipalma, J.R. 1980: Angiotensin-converting enzyme inhibitors American Family Physician 22(5): 164-165
Abe, K. 1985: Angiotensin converting enzyme inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 43(5): 949-955
Renke, M.; Rutkowski, Pław.; Tylicki, L.; Zietkiewicz, M.; Larczyński, W.; Rutkowski, Bław. 2008: Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline Przeglad Lekarski 65(6): 312-314
Vijan, S.G. 2009: Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients Journal of the Indian Medical Association 107(3): 178-182